GLP-1 receptor agonists and HBA1c target of

K. Esposito; C. Mosca; C. Brancario; P. Chiodini; A. Ceriello; D. Giugliano

doi:10.1185/03007995.2011.590127

GLP-1 receptor agonists and HBA1c target of

K. Esposito, C. Mosca, C. Brancario, P. Chiodini, A. Ceriello, D. Giugliano

IRCCS Multimedica

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: Glucagon-like peptide-1 (GLP-1) receptor agonists are available for the treatment of type 2 diabetes. We assessed the efficacy of exenatide and liraglutide to reach the HbA1c target of 2 value=0.513, p

Original language	English
Pages (from-to)	1519-1528
Number of pages	10
Journal	Current Medical Research and Opinion
Volume	27
Issue number	8
DOIs	https://doi.org/10.1185/03007995.2011.590127
Publication status	Published - Aug 2011

Keywords

Clinical trials
Exenatide
GLP-1 analogues
HbA1c <7%
Liraglutide
Type 2 diabetes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1185/03007995.2011.590127

Cite this

@article{dc7cc646e26049278557fcbc663e8b6a,

title = "GLP-1 receptor agonists and HBA1c target of ",

abstract = "Objective: Glucagon-like peptide-1 (GLP-1) receptor agonists are available for the treatment of type 2 diabetes. We assessed the efficacy of exenatide and liraglutide to reach the HbA1c target of 2 value=0.513, p",

keywords = "Clinical trials, Exenatide, GLP-1 analogues, HbA1c <7%, Liraglutide, Type 2 diabetes",

author = "K. Esposito and C. Mosca and C. Brancario and P. Chiodini and A. Ceriello and D. Giugliano",

year = "2011",

month = aug,

doi = "10.1185/03007995.2011.590127",

language = "English",

volume = "27",

pages = "1519--1528",

journal = "Current Medical Research and Opinion",

issn = "0300-7995",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - GLP-1 receptor agonists and HBA1c target of

AU - Esposito, K.

AU - Mosca, C.

AU - Brancario, C.

AU - Chiodini, P.

AU - Ceriello, A.

AU - Giugliano, D.

PY - 2011/8

Y1 - 2011/8

N2 - Objective: Glucagon-like peptide-1 (GLP-1) receptor agonists are available for the treatment of type 2 diabetes. We assessed the efficacy of exenatide and liraglutide to reach the HbA1c target of 2 value=0.513, p

AB - Objective: Glucagon-like peptide-1 (GLP-1) receptor agonists are available for the treatment of type 2 diabetes. We assessed the efficacy of exenatide and liraglutide to reach the HbA1c target of 2 value=0.513, p

KW - Clinical trials

KW - Exenatide

KW - GLP-1 analogues

KW - HbA1c <7%

KW - Liraglutide

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79960435775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960435775&partnerID=8YFLogxK

U2 - 10.1185/03007995.2011.590127

DO - 10.1185/03007995.2011.590127

M3 - Article

C2 - 21663496

AN - SCOPUS:79960435775

VL - 27

SP - 1519

EP - 1528

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 8

ER -

GLP-1 receptor agonists and HBA1c target of

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this